The first therapeutic directed to the LTαβ–LIGHT network, baminercept, an LTβR-Ig fusion protein that neutralizes both LIGHT and LTαβ, was tested in patients with RA (Bienkowska et al., 2014). The gene discussed is LTBR; the disease is rheumatoid arthritis.